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Abstract
Drug-drug interactions have become an important issue in health care. It is now realized that many
drug-drug interactions can be explained by alterations in the metabolic enzymes that are present
in the liver and other extra-hepatic tissues. Many of the major pharmacokinetic interactions
between drugs are due to hepatic cytochrome P450 (P450 or CYP) enzymes being affected by
previous administration of other drugs. After coadministration, some drugs act as potent enzyme
inducers, whereas others are inhibitors. However, reports of enzyme inhibition are very much
more common. Understanding these mechanisms of enzyme inhibition or induction is extremely
important in order to give appropriate multiple-drug therapies. In future, it may help to identify
individuals at greatest risk of drug interactions and adverse events.
Introduction
The cytochrome P450 (P450 or CYP) isoenzymes are a
group of heme-containing enzymes embedded primarily
in the lipid bilayer of the endoplasmic reticulum of hepa-
tocytes, it takes part in the metabolism of many drugs,
steroids and carcinogens [1]. The most intensively studied
route of drug metabolism is the P450-catalysed mixed-
function oxidation reaction which conforms to the fol-
lowing stoichiometry
NADPH + H+ + O2 + RH → NADP+ + H2O + ROH
where, RH represents an oxidisable drug substrate and
ROH is the hydroxylated metabolite, the overall reaction
being catalysed by the enzyme P450. At the present time a
number of CYP isoenzymes are expressed in each mam-
malian species including humans [2], many of these have
specific role involving anabolic steroids and are localized
in the liver. The present system of nomenclature for the
various CYP isozymes employs a three-tiered classifica-
tion based on the conventions of molecular biology: the
family (members of the same family display > 40%
homology in their amino acid sequences), subfamily
(55% homology), and individual gene [3].
This pedigree is indicated by, respectively, an Arabic
numeral (family), a capital letter (subfamily) and another
Arabic numeral (gene), e.g. CYP1A2. The enzymes trans-
forming drugs in humans belong to the CYP families 1–4
and more than 30 human CYP isozymes have been iden-
tified to date. It has been estimated that 90% of human
drug oxidation can be attributed to six main enzymes
(CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4/5). The activities
of the CYP2C19 [4-7] and CYP2D6 [8-14] enzymes are
biomedically distributed in the population, allowing clas-
sification of individuals as either extensive (EM) or poor
metabolizers (PM). The concept that most drug oxida-
tions are catalysed primarily by a small number of P450
enzymes is important in that the approaches to identify-
ing drug-drug interactions are feasible, both in vivo and in
vitro.
More side-effects of drugs and drug-drug interactions are
being reported, as highly effective drugs are developed
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and multiple-drug therapies are increasingly used. Drug
interactions involving the P450 isoforms generally are of
two types: enzyme induction or enzyme inhibition. Com-
mon substrates, inhibitors and inducers of P450 iso-
zymes. Enzyme inhibition reduces metabolism, whereas
induction can increase it. In general, high-extraction drugs
are less affected by these interactions than low-extraction
drugs. As have been shown in recent deaths [15,16]
caused by dysrhythmia or bone marrow (haematopoietic)
inhibition due to combined administration of terfenadine
and ketoconazole [17,18], erythromycin [19] and itraco-
nazole [20], and sorivudine and fluoropyrimidines, are
clinically important and severe interactions do occur. Fur-
thermore, side-effects due to drug-drug interactions in eld-
erly patients because of their reduced physiological
functions are reportedly becoming more frequent and
associated with more severe symptoms; thus, much
importance is being attached to information about drug-
drug interactions when giving any drug therapy. A
number of reviews of these interactions have been pub-
lished [21-63].
In recent years, access to human tissue samples was not
possible in Japan. However, characterization of P450 reac-
tions catalysed by human P450s have been carried out in
the United States and Europe. The availability of the
recombinant human P450s expressed in various systems
has also facilitated studies of their catalytic selectivity [64].
Thus, it is now relatively straightforward to determine in
vitro  interactions in which P450s oxidizes a particular
drug and which drugs can inhibit oxidations catalysed by
this P450. Thus, it is possible to perform logical in vivo
studies to test the relevance of in vitro findings [65,66].
This review discusses interactions and their clinical man-
agement.
P450 enzyme classification
In man there are around 30 CYP enzymes which are
responsible for drug metabolism and these belong to fam-
ilies 1–4. It has been estimated, however, that 90% of
drug oxidation can be attributed to six main enzymes:
CYP 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 [6]. The most sig-
nificant CYP isoenzymes in terms of quantity are CYP3A4
and CYP2D6. CYP3A4 is found not only in the liver but
also in the gut wall, where it may serve as a primary
defence mechanism. The bulk of drugs acting on the CNS
(Central Nervous System), with the exception of volatile
anaesthetic agents, are metabolized by this enzyme.
CYP1A subfamily
CYP1A1 and CYP1A2
The CYP1A family consists of two enzymes, 1A1 and 1A2.
CYP1A1 is not significantly expressed in the liver. It is
found mainly in the lungs, mammary glands, placenta
and lymphocytes. It is an enzyme involved in the inactiva-
tion of procarcinogens and is highly induced by polycyclic
aromatic hydrocarbons (PAHs), which are found in ciga-
rette smoke [7]. There is a strong association between the
activity of CYP1A1 and the risk of lung cancer [8]. CYP1A2
is expressed mainly in the liver and is induced by cigarette
smoking [9]. It is also induced by the ingestion of some
foodstuffs such as cruciferous vegetables as well as barbe-
cued or charbroiled food [10]. Some drugs such as ome-
prazole may induce CYP1A2 activity [11]. Drugs which
are known to be metabolized by CYP1A2 include theo-
phylline, caffeine, imipramine, paracetamol and phenaci-
tin [12]. Alteration in CYP1A2 activity, for example by
smoking, may alter the requirements for theophylline
among asthmatics [13] and haloperidol among psychiat-
ric patients [14]. Caffeine metabolism is also induced by
smoking and explains the increased tolerance to caffeine
among smokers [15].
CYP2 family
CYP2A6, previously known as coumarin hydroxylase, is a
relatively unimportant enzyme in terms of the number of
substrates which it metabolizes, one of the substrates bro-
ken down by this enzyme is nicotine. Differences, both
racial and inter individual, in expression levels are
thought to be related to the propensity to develop nico-
tine dependence [16].
CYP2C subfamily: is one of the most important families
and consists primarily of two enzymes, CYP2C9 and
CYP2C19.
CYP2C9: Among the substrates of CYP2C9 is the anticoag-
ulant warfarin, which exists in two distinct isoforms of
which the S-form is the most important and this is metab-
olized by CYP2C9 [17]. There are a number of polymor-
phisms of the gene that encode this enzyme resulting in
poor metabolic status. These patients may be difficult to sta-
bilize on standard warfarin regimens [18]. Other drugs
metabolized by CYP2C9 include non-steroidal anti-
inflammatory drugs (NSAIDs) (including COX-2 selective
inhibitors), the hypoglycemic agent tolbutamide, pheny-
toin and the angiotensin-II receptor antagonist losartan.
CYP2C19  has a number of commonly used substrates
including the benzodiazepine diazepam, the proton
pump inhibitor omeprazole, propanolol and the antide-
pressive amitriptyline [19]. A number of important abnor-
mal variants of this enzyme exist, one of these has
important clinical consequences. It has been demon-
strated that poor metabolizers who are prescribed proton-
pump inhibitor omeprazole as part of therapy against
Helicobacter pylori infection may have significantly better
clinical outcomes as compared to a group of patients
homozygous for the normal, i.e. wild-type, alleles [20].Nutrition & Metabolism 2008, 5:27 http://www.nutritionandmetabolism.com/content/5/1/27
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CYP2D subfamily
CYP2D6. A large number of drugs are metabolized by this
enzyme including a number of anti-arrhythmics such as
flecanide and encainide, tricyclic antidepressants, some
beta-blockers and a number of selective serotonin re-
uptake inhibitors. It is of particular relevance to anesthet-
ics because a number of commonly used analgesics,
including codeine and tramadol, are broken down by this
enzyme [21]. Previously named debrisoquine hydroxylase
[22], was one of the first to be categorised following rec-
ognition that the metabolism of the hypotensive agent
debrisoquine was abnormal in a proportion of individu-
als. It was renamed CYP2D6 after the parent gene was
cloned and the enzyme categorized [23]. To date, more
than 70 polymorphisms of CYP2D6 have been cata-
logued. The majority of these enzymes result in a poor
metaboliser phenotype as opposed to the normal, i.e.
extensive metabolize phenotype. In addition, a number of
genotypes exist where gene duplication results in an ultra
rapid metabolize status. These patients eliminate CYP2D6
substrates faster than normal and in case of pro-drugs
such as codeine are at greater risk of opiate related side-
effects [24].
CYP2E1
The CYP2E family contains only one enzyme, CYP2E1
(previously dimethylnitrosamine N-demethylase), which
is responsible for the metabolism of small organic com-
pounds such as alcohol and carbon tetrachloride as well
as the halogenated anaesthetic agents halothane, enflu-
rane, diethyl ether, trichloroethylene, chloroform, isoflu-
rane and methoxyflurane [25]. It is also responsible for
the breakdown of many low molecular weight toxins and
carcinogens, many of which are used in manufacturing
and dry cleaning industry, including benzene, styrene,
acetone, vinyl chloride and N-nitrosamines. Some of
these substances are pro carcinogens which are activated
by CYP2E1. There are gender differences in the expression
of the enzyme, obesity and fasting may also affect its activ-
ity [26]. This may provide a putative explanation for obes-
ity related cancers [27].
Because of the key role of CYP2E1 in the biodegradation
of a number of environmental carcinogens, the enzyme
has been studied closely in relation to the causation of
neoplasia. For example, in China an association was
detected between polymorphisms of CYP2E1 and
oesophageal and gastric cancer [28]. There is also mount-
ing evidence that CYP2E1 may be a key factor in the
pathogenesis of alcoholic liver disease [29]. The exact role
of CYP2E1 is unclear, although the enzyme is induced by
both alcohol and nicotine [30], and may explain the
higher ethanol elimination rates among smokers [31].
CYP3A subfamily
CYP3A4 is the most abundantly expressed drug metabo-
lizing enzyme in man responsible for the breakdown of
over 120 different medications and is thus an important
area for study with respect to enzyme based drug interac-
tions. Among the drugs metabolized are sedatives such as
midazolam, triazolam and diazepam, the antidepressives
amitriptyline and imipramine, the anti-arryhthmics ami-
odarone, quinidine, propafenone and disopyramide, the
antihistamines terfenadine, astemizole and loratidine,
calcium channel antagonists such as diltiazem and nifed-
ipine and various antimicrobials and protease inhibitors
[6].
Mechanism of pharmacokinetic drug-drug interaction
Inhibition
Inhibition is reduced enzyme activity due to direct inter-
action with a drug. This process usually begins with the
first dose of the inhibitor, and the start and finish of inhi-
bition correlate with the half-lives of the drugs involved
[67]. There are three basic types of enzyme inhibition
(competitive, non-competitive and uncompetitive), and
clinical effects are influenced by these basic mechanisms
[68,69].
The first type is competitive inhibition between inhibitor
and substrate for the same binding site on an enzyme. The
size and flexibility of the binding site of the microsomal
P450 with which we are concerned here are unknown. For
example, when single oral doses of metoprolol (50 mg), a
beta-adrenoceptor blocking agent and/or propafenone
(150 mg) were administered, or when the two drugs were
given in combination to healthy subjects, an approxi-
mately two-fold reduction in the oral clearance of etopro-
lol was observed when propafenone was included. The
dose of metoprolol should be reduced when propafenone
is also given [70]. Similar drug-drug interactions are seen
in the combined administration of thioridazine and pro-
pranolol (CYP2D6) [71], fluoxetine and desipramine
(CYP2D6) [72], omeprazole and diazepam (CYP2C19)
[73-75], tolbutamide and phenytoin (CYP2C9) [32], and
diltiazem and cyclosporin (CYP3A) [76-78].
The most typical example of the second type of drug-drug
interaction includes that of terfenadine and erythromycin
[19]. The combined use of these drug, terfenadine, and
macrolides (antibiotics) or ketoconazole prolongs elec-
trocardiographic QT intervals, thereby triggering a specific
cardiac dysrhythmia known as torsades de pointes' [18].
The mechanism of this interaction is considered to occur
when a nitro compound, namely a metabolite demethyl-
ated by P450, forms a complex with P450. Since mac-
rolides are catalysed by CYP3A, metabolites selectively
form CYP3A and a stable enzyme-substrate complex
[34,79-81].Nutrition & Metabolism 2008, 5:27 http://www.nutritionandmetabolism.com/content/5/1/27
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In consequence, it has been reported that the metabolism
of drugs like carbamazepine [81-83], midazolam [84-86]
and cyclosporin [87] are catalysed by CYP3A, and their
plasma concentrations are increased when its metabolism
is inhibited by combined use with erythromycin. A P450
species that catalyzes the metabolism of terfenadine was
identified recently as CYP3A [88,89] during investigations
of the mechanism of interactions with macrolides.
Another type is non-competitive inhibition, where the
inhibitor binds at a site on the enzyme distinct from the
substrate, as happens in classical studies of enzymology.
Such examples include interactions between cimetidine
and a number of drugs. The duration of this type of inhi-
bition may be longer if new enzymes are synthesized after
the inhibitor drug is discontinued. Cimetidine is bound to
P450 and produces a stable cytochrome-substrate com-
plex. It is the formation of this complex which prevents
access of other drugs to the P450 system. Cimetidine does
not inhibit conjugation mechanisms including glucuroni-
dation, sulphation and acetylation, or deacetylation or
ethanol dehydrogenation. It binds to the haem portion of
P450 and is, thus, an inhibitor of phase I drug metabolism
reactions (i.e. hydroxylation, dealkylation) [90-92].
Although generally recognized as a nonspecific inhibitor
of this type of metabolism, cimetidine does demonstrate
some degree of specificity. Since every molecular species
of P450 has a haem portion, it is possible for cimetidine
to nonspecifically inhibit any drug that is metabolized by
any molecular species. However, in a recent study that
compared the inhibitory effect of several P450 isozymes
in a study using drugs such as ketoconazole, clotrimazole,
miconazole, fluconazole, secnidazole and metronidazole,
all imidazole derivatives [92,93], it was reported that iso-
niazid, an antituberculous drug, inhibits the metabolism
of phenytoin [94]. As for its inhibitory mechanism, it is
conceivable that there is an interaction between the
hydrazino group of isoniazid and the haem portion of
P450. As far as ethinylestradiol, an oral contraceptive, is
concerned, the CYP3A isozyme is one of the major forms
involved in its 2-hydroxylation [93,95,96]. Guengerich
reported that in vitro it is a relatively effective and selective
mechanism-based inactivator of CYP3A4 [96]. This inacti-
vation is due in part to the presence of an ethynyl moiety,
which is also found in many inactivators [93-97].
Induction
The effect of induction is simply to increase the amount of
P450 present and speed up the oxidation and clearance of
a drug [67]. It is rather difficult to predict the time-course
of enzyme induction because of several factors, including
the drug half-life and enzyme turnover, which determine
the time-course of induction. A complicating factor is that
the time-course of induction depends on the time
required for enzyme degradation and new enzyme pro-
duction. The short half-life of rifampicin results in
enzyme induction (CYP3A4, CYP2C), apparent within 24
h, whereas phenobarbital, which has a half-life of 3–5
days, requires ≅1 week for induction (CYP3A4, CYP1A2,
CYP2C) to become apparent. These enzyme-induction
reactions also occur with smoking and long-term alcohol
or drug consumption and can reduce the duration of
action of a drug by increasing its metabolic elimination.
Of all these drugs, the clinically most problematic drug
involves the rifampicin series [98-106] which includes
antiepileptic drugs such as phenobarbital [107,108], car-
bamazepine [109,110] and phenytoin [108,110] and
antituberculous drugs [110]. The CYP1A2 enzyme can be
induced by exposure to polycyclic aromatic hydrocar-
bons, such as are found in char-grilled foods and cigarette
smoke [111,112]. Most human CYP2C and 3A subfamily
proteins are induced by barbiturates [113], while human
CYP2E1 is inducible by ethanol and isoniazid, although
the mechanism involved is complex [114,115]. One
example has been described by Lee et al. [99] who
reported that changes in the pharmacokinetics of pred-
nisolone were caused by administration or discontinua-
tion of rifampicin. Pharmacokinetic studies of
prednisolone (1 mg/kg) in patients over a 1-month period
of rifampicin co-treatment or after its withdrawal revealed
significant changes in the area under the curve (AUC),
total body clearance, non-renal clearance and half-life. As
mentioned earlier, rifampicin is possibly associated with
plural molecular species of P450 (several isozymes), but
mainly, a large increase in the CYP3A content often
becomes a problem, while phenobarbital, carbamazepine
and phenytoin, antiepileptic drugs, also induce CYP3A
[32]. Thus, appropriate therapeutic effects can hardly be
obtained unless the doses are increased significantly, since
plasma concentrations are not elevated in patients receiv-
ing these drugs which are metabolized by CYP3A. The
P450 isoenzymes induced by exposure to polycyclic aro-
matic hydrocarbons, such as those found in char-grilled
foods and cigarette smoke, are CYPlAl and CYP1A2
[116,117]. CYPIA2 is a molecular species of P450 which
participates in the metabolism of several important drugs
such as theophylline and propranolol and, since its activ-
ity is enhanced by smoking and eating grilled meat or cru-
ciferous vegetables, it is difficult to obtain therapeutic
effects. Although CYP2C9, CYP2C19 and CYP2E1 are also
induced, no specific inducers of CYP2D6 have yet been
identified clearly. However, it appears to be inducible.
Mechanism of non-microsomal pharmacokinetic drug-drug 
interactions
Sixteen Japanese patients died when given both sorivu-
dine and fluoropyrimidines orally. Sorivudine is a potent
inhibitor of hepatic dihydropyrimidine dehydrogenase,
the enzyme responsible for the catabolism of fluoropyri-
midines. Therefore, the fluoropyrimidine levels in theseNutrition & Metabolism 2008, 5:27 http://www.nutritionandmetabolism.com/content/5/1/27
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patients reached toxic levels due to the inhibition of dihy-
dropyrimidine dehydrogenase by sorivudine [15,16].
Clinical example of P450-based interactions
Terfenadine
Terfenadine is the first non-sedating H1-antihistamine
drug. It is rapidly oxidized by CYP3A4 to two metabolites,
acyclinol and an alcohol derived from the oxidation of a
t-butyl methyl group [118]. The alcohol is further oxi-
dized to a carboxylic acid by either CYP3A4 or dehydroge-
nase [119]. This carboxylic acid then binds to the H1
histamine receptor and should relieve allergy symptoms.
The oxidation of terfenadine by CYP3A4 can be inhibited
strongly by azole antifungal or antimicrobial agents such
as ketoconazole [17,18] and erythromycin [19]. For exam-
ple, Honing et al. [18] performed experiments on six
healthy volunteers (four men and two women, aged 24–
35 years). After achieving a steady-state while taking ter-
fenadine (60 mg every 12 h for 7 days), daily concomitant
oral ketoconazole (200 mg every 12 h) was added to the
regimen. Pharmacokinetic profiles were obtained while
subjects were taking terfenadine alone and after the addi-
tion of ketoconazole. Electrocardiograms were obtained
at baseline, after 1 week of taking terfenadine alone, and
at the time of the second pharmacokinetic profile after the
addition of ketoconazole to the regimen. Serum concen-
trations of terfenadine and its acid metabolite and cor-
rected QT intervals were obtained. All subjects had
detectable levels of unmetabolized terfenadine after the
addition of ketoconazole, associated with QT prolonga-
tion. Only two of the six subjects were able to complete
the entire course of ketoconazole coadministration. Four
subjects received a shortened period of ketoconazole ther-
apy because of significant electrocardiographic repolariza-
tion abnormalities. There was a significant reduction in
the AUC of the acid metabolite of terfenadine during keto-
conazole administration. Therefore, the blood concentra-
tion of terfenadine increased. High blood levels of
terfenadine have been associated with cardiac problems
including dysrhythmias, torsade de pointes, and abnor-
mal ventricular rhythms. For this reason, very carefully
controlled co-administration of terfenadine is advised.
Cimetidine
Cimetidine inhibits antihistamine H2-receptor binding
and is used in the treatment of gastric ulcers. The mecha-
nism of inhibition appears to involve the imidazole ring
of cimetidine with competitive binding, which is not
present in ranitidine [90,91]; it also exhibits selective inhi-
bition of reactions catalysed by CYP2D6 and 3A4 [90,92-
120]. For example, unlike ranitidine, cimetidine signifi-
cantly increased the maximum plasma concentration
(Cmax), AUC and the total amount of disopyramide
excreted unchanged in the urine, but the serum profile of
mono-N-dealkyldisopyramide, a metabolite of disopyra-
mide, was not affected significantly. Ranitidine had no
significant effect on the pharmacokinetics of disopyra-
mide and mono-N-dealkyldisopyramide. These results
indicate that cimetidine, but not ranitidine, significantly
increases the absorption of oral disopyramide [121]. Tan-
aka and Nakamura also investigated the effects of H2-
receptor antagonists (cimetidine, ranitidine, and famoti-
dine) on ethanol metabolism. In both aldehyde dehydro-
genase (ALDH)-1 deficient subjects and in those with
normal ALDH-1, the three H2-receptor antagonists and
placebo had similar effects on the pharmacokinetic
parameters of ethanol, i.e. peak time (tmax), metabolic
rate, Cmax, volume of distribution (Vd) and AUC. The
AUC of acetaldehyde was slightly (P < 0.05) but signifi-
cantly greater only after treatment with cimetidine; the
Cmax and tmax of acetaldehyde were unchanged [122]. As
mentioned above, there are a number of drugs whose
metabolism is inhibited when cimetidine is administered
in combination [90-92].
Grapefruit juice
The opportunity for a food-drug interaction is an everyday
occurrence, which can be particularly important when
total drug absorption is altered. Recently, a chance obser-
vation led to the finding that grapefruit juice could mark-
edly increase the oral bioavailability of a number of
medications [123]. This article retraces discovery of this
novel interaction and reviews the mechanism of action,
summaries studied and predicted medications for an
interaction, discusses possible active ingredient in the
juice and considers clinical implications. In 1989 it was
reported that coadministration of grapefruit juice with the
calcium channel antagonist felodipine resulted in a large
increase in serum felodipine concentrations, as well as an
enhancement of the pharmacodynamic effects of the drug
[124].
Some drugs exhibit a significantly increased (up to three-
fold) mean oral bioavailability when co-administered
with grapefruit juice. Bailey et al [125] reported that the
inhibitory effect of grapefruit juice was discovered rather
serendipitously in an interaction study with ethanol and
felodipine, a 1,4-dihydropyridine calcium entry blocker.
Flavonoids (e.g. quercetin, naringenin, kaempferol)
found in large amounts in oranges, grapefruit and their
juices are known to alter the activity of P450 enzymes
(P450 isoenzyme). The mechanism of inhibition of drug
oxidation probably involves intestinal CYP3A4. The
major grapefruit-specific flavonoid is naringin, which can
account for up to 10% of the dry weight. It is believed that
this naringin mainly inhibits the enzyme (CYP3A) that
metabolizes calcium antagonists. For example, interac-
tions between benzodiazepines (e.g. midazolam, tria-
zolam), antihistamines (e.g. terfenadine), immuno-
suppressive drugs (e.g. cyclosporin) and grapefruit juiceNutrition & Metabolism 2008, 5:27 http://www.nutritionandmetabolism.com/content/5/1/27
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have been reported [125]. For example, Hukkinen et al.
[126] studied 10 healthy young subjects who received a
single 0.25 mg dose of triazolam with either 250 ml grape-
fruit juice or water. The plasma concentrations and effects
of triazolam were measured up to 17 h. Grapefruit juice
increased the AUC of triazolam in each subject and the
Cmax in nine out of 10 subjects. The mean AUC of tria-
zolam increased 1.5-fold (P < 0.001) and the peak con-
centration increased 1.3-fold (P  < 0.05) following
grapefruit juice. Grapefruit juice also postponed the peak
time of triazolam from 1.6 to 2.5 h (P < 0.05). Grapefruit
juice also increased the effects of triazolam, drowsiness
being significantly (P < 0.05) enhanced. However, as it
has been described in a paper [127] that other flavonoids
(quercetin for example) may be major inhibitors of
metabolism, the results of future studies are awaited with
interest. On the other hand, it is reported that naringin
also inhibits the demethylation (N-demethylation) of caf-
feine, metabolized by CYPIA2 [125]. It has already been
established that, grape fruit juice is well known as potent
inhibitors of cytochrome P450 3A4 activity. It increases
bioavailability of several drugs known to be metabolized
by CYP3A4, while on the other hand interact and block
the activity of ciprofloxacin, ofloxacin, cefazolin and ceft-
izixime. Owing to clinical relevance of grapefruit juice-
drug interactions, an investigation of drug interactions of
two quinolones, ciprofloxacin and ofloxacin were investi-
gated in vitro with all the fruit juices available locally at
human body temperature [128]. A single glass of grape-
fruit juice has the potential to augment the oral bioavail-
ability and to enhance the beneficial or adverse effects of
a broad range of medications, even by juice consumed
hours beforehand. Grapefruit juice acts by inhibiting pre-
systemic drug metabolism mediated by CYP3A isoforms
in the small bowel. The interaction appears particularly
relevant for medications with at least a doubling of
plasma drug concentration or with a steep concentration-
response relationship or a narrow therapeutic index.
Patients that appear particularly susceptible have high
small bowel CYP3A4 content, hepatic insufficiency or a
pre-existing medical condition, which predisposes to
enhanced, excessive or abnormal drug effects [129].
Omeprazole
Omeprazole is a proton-pump inhibitor used widely for
the treatment of gastric ulcers [53,62]. Omeprazole is con-
verted to hydroxyomeprazole and omeprazole sulphone
primarily by CYP2C19 and CYP3A4, respectively. Gugler
and Jensen first reported that omeprazole reduced the
plasma clearance and prolonged the half-life of phenytoin
and diazepam but did not affect the apparent volume of
distribution and plasma protein binding of either
diazepam or phenytoin [130]. Recently, in a pharmacoge-
netic study, Anderson et al. [131] studied the effect of
omeprazole treatment on diazepam plasma levels in 6 EM
and 4 PM of omeprazole. Single i.v. doses of diazepam
(0.1 mg/kg) were administered after 1 week of oral ome-
prazole (20 mg) and placebo. The slow metabolizers of
omeprazole also metabolized diazepam slowly, exhibit-
ing only half the diazepam plasma clearance of the others.
The mean clearance of diazepam fell 26% after omepra-
zole in the rapid metabolizers, whereas the slow group
showed no apparent interaction. Desmethyldiazepam
was formed more rapidly in the rapid compared with the
slow metabolizers, which is a logical consequence of the
rate of diazepam metabolism. In the light of these results,
omeprazole appears to be a competitive inhibitor of
CYP2C19, and involved in its metabolism. These data
show that omeprazole interferes with the elimination of
other drugs by inhibiting the mixed function oxidases of
human liver. Other acid pump inhibitors (lansoprazole or
pantoprazole) are also mainly metabolized by CYP2C19.
For drugs metabolized by CYP2C19, such as 5-mepheny-
toin, imipramine or diazepam, their metabolism is inhib-
ited [132].
Erythromycin
Erythromycin, an antimicrobial agent, is known to inhibit
a number of drug oxidation reactions catalysed by
CYP3A4 [80]. It inhibits the oxidation of terfenadine
[19,133], cyclosporin [134] and numerous other drugs
both in vivo and in vitro and erythromycin N-demethyla-
tion itself is catalysed by CYP3A4/5 [135,136]. However,
not all CYP3A4 reactions are inhibited by erythromycin.
As far as the above results are concerned, Guengerich [56]
has made the following two proposals: i lack of inhibition
of a reaction by erythromycin may not always be a reliable
indication that the reaction is not catalysed by CYP3A4
and (ii) not all CYP3A4-catalysed reactions may be prone
to erythromycin interactions. The reasons for this are not
clear at the moment.
Cyclosporin
Cyclosporin is the most popular immunosupressant used
in organ transplantation. The major pathway of
cyclosporin metabolism is via CYP3A4 [137,138], with
three major metabolites being formed [139]. Since
cyclosporin is mainly used as an immunosuppressant for
organ transplantation, the CYP3A4 level in the donor's
liver as well as the recipient's liver, small intestine and
other tissues must always be taken into consideration. For
example, Lucey et al. [140] reported that a 40-year-old
male liver allograft recipient had neurological dysfunction
and renal failure while his cyclosporin blood levels were
in the therapeutic range. CYP3A activity, using the [14C]
erythromycin breath test, was reduced compared with that
in controls, including other liver transplant recipients.
Pretreatment with rifampicin, an inducer of CYP3A,
increased enzyme activity. After treatment with rifampicin
the patient was able to be rechallenged with cyclosporinNutrition & Metabolism 2008, 5:27 http://www.nutritionandmetabolism.com/content/5/1/27
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at a dose almost twice that which had previously been
toxic. The patient died during a second transplantation
and the microsomal CYP3A content was found to be low
in the first transplant liver. Lower blood levels of
cyclosporin may have been achieved when the drug used
for enzyme induction (rifampicin) has been given to the
transplant patient for a long period [140].
Rifampicin
Rifampicin [98-106,141,142] and isoniazid [101] are key
drugs used in the treatment of tuberculosis, while
rifampicin is highly effective in inducing hepatic, drug
metabolic P450 enzyme. When enzyme induction is
achieved, the pharmacological effects of a specific drug
may be reduced, since not only the metabolism of
rifampicin itself, but also the metabolism of the other
drug is accelerated [136]. The problem arises when doses
are increased to reduce the effects of the combined drugs:
increased serum concentrations of the combined drugs
may possibly produce side-effects because of the lost
enzyme induction if rifampicin is discontinued.
Rifampicin is also known to induce CYP3A4 and CYP2C9
(e.g. cyclosporin, diazepam and steroids). As for dihydro-
pyridine calcium channel blockers, it is quite possible that
interactions with rifampicin may develop, since most of
these drugs are metabolized by CYP3A4 [143-150,129].
Conclusion
There are two main types of drug interaction: pharmacok-
inetic and pharmacodynamic. Pharmacokinetic interac-
tions involve the effect of one drug on the absorption,
metabolism, excretion or protein binding of another drug.
On the other hand, pharmacodynamic interactions are
caused by several effects (additive, synergistic or antago-
nistic effects) of the combined treatment at the site of bio-
logical activity, changing the pharmacological action of
the drugs, even at standard blood concentrations. Phar-
macokinetic interactions focused on P450 are described
in this paper. The incidence of side-effects is markedly
higher in the elderly and those with more severe symp-
toms. Thus, understanding the mechanism underlying
drug interactions is useful, not only in preventing drug
toxicity or adverse effects, but also in devising safer thera-
pies for disease.
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